Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: impact of early MRD kinetics on posttreatment outcomes Jacob Soumerai , Ahmet Dogan , Venkatraman Seshan , Kelsey Flaherty , Jason Carter , Ephraim Hochberg , Jeffrey Barnes , Jeremy Abramson , Audrey Hamilton , Ariela Noy , Colette Owens , M. Lia Palomba , Anita Kumar , Lindsey Roeker , Meghan Thompson , Ronald Takvorian , Zachary Epstein-Peterson , Mark Geyer , Walter Ramos-Amador , Neena Mahajan , Rosalba Martignetti , Sean Plummer , Joanna Mi , Julia Lynch , Brianne McGree , Maryanne Sherburne , Emily Patterson , Natalie Slupe , Maria Chabowska , Alyssa Labarre , Morgan Choma , Grace McCambridge , Hailey Kelly , Mary Devlin , Madeline Puccio , Rayna Garcia , Clare Grieve , Aileen Cohen , Juliana Biondo , Allison Jacob , Omar Abdel-Wahab , Andrew Zelenetz LEUKEMIA & LYMPHOMA（2023）
AI 理解论文
溯源树
样例
